We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Cytomyx Hldgs | LSE:CYX | London | Ordinary Share | GB0033942276 | ORD 2.5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.10 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
13/10/2004 15:18 | Below, just a reminder of the August update. It didn't stop it from bottoming a shade over 13p in Sept. It will probably drift until a week or two before finals. Last year were in mid-December. However, good figures add up quicker so if earlier this year that will be a good sign in itself. 24/08/04 LONDON (AFX) - Cytomyx Holdings PLC, a provider of drug discovery products and services, said it narrowed its third quarter net loss on higher margins and a rise in sales. In the six months to June, sales rose to 1.52 mln stg compared with 1.34 mln stg while consolidated profit before interest, goodwill and intangibles stood at 19,000 stg versus a loss of 232,000 stg year-on-year. Net loss narrowed to 39,000 stg from 245,000 previously. The gross margin in the third quarter was 61 pct, compared with 51 pct in the second quarter of 2004 and 46 pct in the third quarter of 2003, reflecting the growing impact of internally developed products and services over the distribution of lower margin third-party products. newsdesk@afxnews.com ra | boadicea | |
13/10/2004 07:41 | Time to get in big time coming.............. | irshaad | |
04/10/2004 13:03 | Well these relatively low offer prices struck compared to the official offer are certainly confusing the ADVFN computer. Your 50k., brownie, is showing as a sell as is, I believe, another. My 12k. buy is shown as a ? Just one of the 4 deals is actually shown, I believe correctly, as a buy. Agree with you the size of the spread is totally unfair and, in my view, unsustainable. aj. | ajrice | |
04/10/2004 11:44 | I just told my broker the price I was prepared to pay and he posted it into the electronic trading system and it got hit right away. MM's should be ashamed of size of spread they are quoting here; 2.5p on bid of 15p (16.67%) jeez. | brownie69 | |
04/10/2004 10:59 | > brownie69: Just topped up with (a more modest) 12,000. Best I could get was 16.25p but my broker at first quoted 17.5p! aj. | ajrice | |
04/10/2004 10:27 | A nice pharma nice business rolling onwards towards profit. Teathers now starting a big push with overhang gone. Director buying a big clue in how its going. I've decided to top up. 50k bought at 16p was me, not yet on screen will show as a late trade. More to come if MM's will hold back a bit longer:-) | brownie69 | |
01/10/2004 10:10 | ........the rise continues; looking good imho. aj. | ajrice | |
30/9/2004 17:28 | Agree; The chairman's 100,000 purchase today, making his total holding 340,000 is in my opinion a real commitment and should give us shareholders a good degree of confidence in CYX. aj. | ajrice | |
30/9/2004 16:21 | Director dealing, looks ready to rock and ROLL!!!!1 | irshaad | |
30/9/2004 11:43 | Still continues to rise; this am another .25p with no trades and no news. Guess either mm's have to fill a large order or they know something we don't. aj. | ajrice | |
30/9/2004 09:33 | I have not looked at this one for quite a time and seeing how its share price had declined, assumed it was a bit of a no-hoper. However, then looked at latest two reports (May interims and Aug 3rd qtr) and am surprised to find it seems to have turned the corner. Reason for gloom after the interims was possibly the loss of the the Molecular Probes distribution agreement. Cash flow was also not good for the preceding 12 months, i.e. 2nd half 2003 + first half 2004. The August 3rd quarter figures show that turnover has not suffered as much as could have been feared from the distribution loss and break-even is approaching. This share is not alone in having an illogical chart. There may be an overhang and/or general lack of recognition coupled with a jaundiced historical view. However, looks like it's time to get in, imho - but dyor. | boadicea | |
27/9/2004 11:58 | ...............and still she rises! Looking good imho. aj. | ajrice | |
24/9/2004 13:53 | Bloody hell - another tick up - Im watching too ok,yah, though have pretty much written off this investment! You never know though! | raldo | |
24/9/2004 10:06 | talking to myself I know but you can sell at 13.70 with e trade suggests theres a buyer around. | ok,yah | |
23/9/2004 12:00 | Good to know i'm not the only one watching these! By rights this is much too cheap already the company is operating in a growing sector and have not issued bad news since the price was at its peak 50p - They are predicted to make profits next year. They seem just to have fell off the radar with a lot of small caps drifting down this has suffered more than most. The bid is up today first time in ages on a down day. With yesterdays largeish volume i'm hoping this is turning the corner. Certainly does not look to have been large selling on the way down so always has the potential to move up quickly on good news. | ok,yah | |
22/9/2004 17:11 | Highest volume for ages today - but a fall (again), where is this going to?? | raldo | |
22/9/2004 09:48 | Well bought these for the first time today - They actually trade as a discount to Net asset Value now (see interim results). The last fundraising was at 32.5p since then there has been news on lots of positive deals, and margins and turnover have been improving. | ok,yah | |
24/8/2004 15:02 | ajrice : I take comfort in your words. You're right, they're a sound little company but very low profile. Be careful if you're topping up, many think averaging down is always a bad idea. Be lucky! | snowman69 | |
24/8/2004 10:17 | >Snowman69: IMHO if you'd operated a stop loss position with CYX you would very likely have taken a loss and you would not now be able to benefit from a company which has already turned the corner. Very few small cap companies can report such excellent figures; i.e. increased turnover combined with much higher margins. My own average cost per share is 39p but I am comforted in the knowledge that CYX will continue to outperform in the coming financial year. I will be topping up today. All imho., dyor etc. aj. | ajrice | |
24/8/2004 08:34 | They've looked pretty solid since I bought in early January this year but the share price has fallen through the floor. The consolidation was a disaster and I'm well over 50% down for no apparent reason. I must master the concept of the stop loss! Be lucky! | snowman69 | |
24/8/2004 07:53 | GOOD RESULTS TODAY: Looks like CYX is finally turning the corner - turover up, losses down significantly and business doing well ... Cytomyx Holdings plc (AIM: CYX), a leading provider of drug discovery products and services, today announces unaudited financial results for the three-month period ended 30 June 2004. The Group reported turnover of £1.52m, compared with £1.34m for the corresponding period in 2003, and a consolidated profit before interest and amortisation of goodwill and intangibles of £19,000, compared with a loss of (£232,000) for the same period in 2003. The gross margin in the third quarter was 61%, compared with 51% in the second quarter of 2004 and 46% in the third quarter of 2003. This reflects the growing impact of internally developed products and services over the distribution of lower margin third-party products, which offset the impact on sales at the Cambridge BioScience unit due to the previously announced termination of a distribution agreement. The profit in the quarter was attributed to the significant investment that was made in the Clinomics Biosciences and Cytomyx Limited businesses in the first half of the year, resulting in higher margin products that include Ion Channel cell lines, Tissue MicroArrays and Human Biology Database services. Commenting on these results, Mike Kerins, Chief Executive said: 'Our third quarter results are pleasing because they reflect a continuing trend of revenue growth and improving operating margins. We are seeing strong demand for Cytomyx Limited's Ion Channel cell lines and the unique services that Clinomics is providing to its clients in the pharmaceutical industry. We plan to continue our investment in these two high growth operations. | sandbank | |
16/7/2004 17:47 | .............sorry, make that almost 3 years to the day. aj. | ajrice | |
16/7/2004 17:46 | I bought mine almost two years ago to the day (18th July '01) via Everett @ 6.5p. Have since averaged down to the 1:25 split price of 39p so I'm around 56% down. That'll teach me to average down! LOL aj. | ajrice | |
16/7/2004 13:55 | jon have had my shares about 2years got them from hoodwink & brennan that was before i found out about there reputation | metamick |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions